Zhang, C.; Sheng, W.; Al-Rawe, M.; Mohiuddin, T.M.; Niebert, M.; Zeppernick, F.; Meihold-Heerlein, I.; Hussain, A.F.
EpCAM- and EGFR-Specific Antibody Drug Conjugates for Triple-Negative Breast Cancer Treatment. Int. J. Mol. Sci. 2022, 23, 6122.
https://doi.org/10.3390/ijms23116122
AMA Style
Zhang C, Sheng W, Al-Rawe M, Mohiuddin TM, Niebert M, Zeppernick F, Meihold-Heerlein I, Hussain AF.
EpCAM- and EGFR-Specific Antibody Drug Conjugates for Triple-Negative Breast Cancer Treatment. International Journal of Molecular Sciences. 2022; 23(11):6122.
https://doi.org/10.3390/ijms23116122
Chicago/Turabian Style
Zhang, Chaoyu, Wenjie Sheng, Marwah Al-Rawe, T. M. Mohiuddin, Marcus Niebert, Felix Zeppernick, Ivo Meihold-Heerlein, and Ahmad Fawzi Hussain.
2022. "EpCAM- and EGFR-Specific Antibody Drug Conjugates for Triple-Negative Breast Cancer Treatment" International Journal of Molecular Sciences 23, no. 11: 6122.
https://doi.org/10.3390/ijms23116122
APA Style
Zhang, C., Sheng, W., Al-Rawe, M., Mohiuddin, T. M., Niebert, M., Zeppernick, F., Meihold-Heerlein, I., & Hussain, A. F.
(2022). EpCAM- and EGFR-Specific Antibody Drug Conjugates for Triple-Negative Breast Cancer Treatment. International Journal of Molecular Sciences, 23(11), 6122.
https://doi.org/10.3390/ijms23116122